Plasma Metanephrines Are Associated With Glucose Metabolism in Patients With Essential Hypertension

Weiqing Wang, Liangshan Mu, Tingwei Su, Lei Ye, Yiran Jiang, Lei Jiang, Weiwei Zhou, Weiqing Wang, Liangshan Mu, Tingwei Su, Lei Ye, Yiran Jiang, Lei Jiang, Weiwei Zhou

Abstract

There is a high incidence of glucose intolerance in essential hypertension. Overactivation of the sympathetic system is one of important causes of essential hypertension. Whether sympathetic system affects glucose metabolism in patients with essential hypertension has never been reported previously. The aim of this study was to explore the association between the sympathetic system activity and glucose metabolism in patients with essential hypertension. A total of 202 essential hypertension inpatients without diabetes were recruited from Shanghai Ruijin Hospital between February 2006 and August 2013. Activity of sympathetic system was quantified by plasma metanephrines (MNs) levels. All subjects received an oral glucose tolerance test. Fasting plasma glucose and 2-hour plasma glucose increased significantly across the quartiles of plasma MNs. The multiple linear regression analysis revealed that plasma MNs were significantly associated with fasting plasma glucose and 2-hour plasma glucose. The area under curve of plasma glucose increased significantly from the lowest plasma MNs quartile across to the highest quartile. The multiple logistic regression analysis revealed that odds ratios (95% confidence interval) for prediabetes in the highest quartile compared with the lowest quartile of plasma MNs was 4.00 (95% confidence interval, 1.16-13.86). Plasma MNs levels are positively associated with plasma glucose in patients with essential hypertension. Patients with high plasma MNs levels had an increased risk of prediabetes.

Conflict of interest statement

There are no conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Plasma glucose concentrations and the AUC of plasma glucose according to plasma MNs quartiles during the OGTT test. A, plasma glucose concentrations according to plasma MNs quartiles; B, the AUC of plasma glucose according to plasma MNs quartiles. P values and P for trend were adjusted for age, sex, body mass index, systolic blood pressure, current smoking state, total cholesterol. Data are mean ± SEM; ∗P < 0.05; ∗∗P < 0.01. AUC = area under curve, MNs = metanephrines, OGTT = oral glucose tolerance test. This figure suggests significant associations between plasma MNs and plasma glucose levels.

References

    1. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation 2000; 101:329–335.25.
    1. Long AN, Dagogo-Jack S. Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich Conn) 2011; 13:244–251.
    1. Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet 2012; 380:601–610.
    1. Reiche EMV, Nunes SOV, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol 2004; 5:617–625.
    1. Mancia G, Bousquet P, Elghozi JL, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007; 25:909–920.
    1. Levy MN. Brief reviews sympathetic-parasympathetic interactions in the heart. Circ Res 1971; 29:437–445.
    1. Grassi G. Role of the sympathetic nervous system in human hypertension. J Hypertens 1998; 16:1979–1987.
    1. Jennings GL. Noradrenaline spillover and microneurography measurements in patients with primary hypertension. J Hypertens 1998; 16:S35–38.
    1. Esler M. The sympathetic system and hypertension. Am J Hypertens 2000; 13:99S–105S.
    1. Greenwood JP, Stoker JB, Mary DA. Single-unit sympathetic discharge quantitative assessment in human hypertensive disease. Circulation 1999; 100:1305–1310.
    1. Alvarez GE, Beske SD, Ballard TP, et al. Sympathetic neural activation in visceral obesity. Circulation 2002; 106:2533–2536.
    1. Vollenweider P, Tappy L, Randin D, et al. Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest 1993; 92:147.
    1. Huggett RJ, Scott EM, Gilbey SG, et al. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 2003; 108:3097–3101.
    1. Eisenhofer G, Keiser H, Friberg P, et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 1998; 83:2175–2185.
    1. Eisenhofer G, Friberg P, Pacak K, et al. Plasma metadrenalines: do they provide useful information about sympatho-adrenal function and catecholamine metabolism? Clin Sci 1995; 88:533–542.
    1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42:1206–1252.
    1. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317:350–357.
    1. Sironi AM, Gastaldelli A, Mari A, et al. Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension 2004; 44:127–133.
    1. Varughese GI, Lip GY. Hypertension in patients with type-II diabetes: relation to urinary albumin excretion, endothelial function and inflammation. J Hum Hypertens 2005; 19:421–424.
    1. Flaa A, Aksnes TA, Kjeldsen SE, et al. Increased sympathetic reactivity may predict insulin resistance: an 18-year follow-up study. Metabolism 2008; 57:1422–1427.
    1. Masuo K, Mikami H, Ogihara T, et al. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am J Hypertens 1997; 10:77–83.
    1. Masuo K, Mikami H, Ogihara T, et al. Weight gain: induced blood pressure elevation. Hypertension 2000; 35:1135–1140.
    1. Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42:474–480.
    1. Goldstein DS. Plasma catecholamines and essential hypertension. An analytical review. Hypertension 1983; 5:86–99.
    1. Franco-Morselli R, Elghozi J, Joly E, et al. Increased plasma adrenaline concentrations in benign essential hypertension. BMJ 1977; 2:1251.
    1. Gudmundsdottir H, Strand AH, Høieggen A, et al. Do screening blood pressure and plasma catecholamines predict development of hypertension? Twenty-year follow-up of middle-aged men. Blood Press 2008; 17:94–103.
    1. Diamanti-Kandarakis E, Zapanti E, Peridis MH, et al. Insulin resistance in pheochromocytoma improves more by surgical rather than by medical treatment. Hormones (Athens, Greece) 2003; 2:61–66.
    1. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 2000; 43:533–549.
    1. Laurent D, Petersen KF, Russell RR, et al. Effect of epinephrine on muscle glycogenolysis and insulin-stimulated muscle glycogen synthesis in humans. Am J Physiol 1998; 274:E130–138.
    1. Chu CA, Sindelar DK, Neal DW, et al. Effect of a selective rise in sinusoidal norepinephrine on HGP is due to an increase in glycogenolysis. Am J Physiol Endocrinol Metab 1998; 274:E162–E171.
    1. Jones C, Ritchie J. The metabolic and endocrine effects of circulating catecholamines in fetal sheep. J Physiol 1978; 285:395–408.
    1. Zelinka T, Petrak O, Strauch B, et al. Elevated inflammation markers in pheochromocytoma compared to other forms of hypertension. Neuroimmunomodulation 2007; 14:57–64.
    1. Petrak O, Strauch B, Zelinka T, et al. Factors influencing arterial stiffness in pheochromocytoma and effect of adrenalectomy. Hypertens Res 2010; 33:454–459.
    1. Bosanska L, Petrak O, Zelinka T, et al. The effect of pheochromocytoma treatment on subclinical inflammation and endocrine function of adipose tissue. Physiol Res 2009; 58:319–325.
    1. Dandona P, Aljada A, Chaudhuri A, et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 22: 111:1448–1454.
    1. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27:813–823.
    1. Montecucco F, Pende A, Quercioli A, et al. Inflammation in the pathophysiology of essential hypertension. J Nephrol 2011; 24:23–34.
    1. Mohamed-Ali V, Flower L, Sethi J, et al. beta-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab 2001; 86:5864–5869.
    1. Stefanadi E, Tousoulis D, Androulakis ES, et al. Inflammatory markers in essential hypertension: potential clinical implications. Curr Vasc Pharmacol 2010; 8:509–516.
    1. Muller S, Martin S, Koenig W, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002; 45:805–812.
    1. Temelkova-Kurktschiev T, Siegert G, Bergmann S, et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 2002; 51:743–749.
    1. Temelkova-Kurktschiev T, Henkel E, Koehler C, et al. Subclinical inflammation in newly detected Type II diabetes and impaired glucose tolerance. Diabetologia 2002; 45:151.
    1. Grassi G. Sympathetic neural activity in hypertension and related diseases. Am J Hypertens 2010; 23:1052–1060.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться